Hans Lennerns

List of Publications by Year in Descending Order

178 papers	12,542 citations	49 h-index	110 g-index
189 ext. papers	13,535 ext. citations	4.2 avg, IF	6.34 L-index

#	Paper	IF	Citations
178	Drug Resistance and Endoplasmic Reticulum Stress in Hepatocellular Carcinoma.. *Cells*, **2022**, 11,	7.9	5
177	Drug diffusion in biomimetic hydrogels: importance for drug transport and delivery in non-vascular tumor tissue.. *European Journal of Pharmaceutical Sciences*, **2022**, 106150	5.1	1
176	Best practices in current models mimicking drug permeability in the gastrointestinal tract - an UNGAP review.. *European Journal of Pharmaceutical Sciences*, **2021**, 170, 106098	5.1	3
175	Melatonin-Activated Receptor Signaling Pathways Mediate Protective Effects on Surfactant-Induced Increase in Jejunal Mucosal Permeability in Rats. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	1
174	Chemotherapeutics-Induced Intestinal Mucositis: Pathophysiology and Potential Treatment Strategies. *Frontiers in Pharmacology*, **2021**, 12, 681417	5.6	8
173	Anthracyclins Increase PUFAs: Potential Implications in ER Stress and Cell Death. *Cells*, **2021**, 10,	7.9	3
172	In Vitro Cell Toxicity and Intracellular Uptake of Doxorubicin Exposed as a Solution or Liposomes: Implications for Treatment of Hepatocellular Carcinoma. *Cells*, **2021**, 10,	7.9	5
171	Oral Drug Delivery, Absorption and Bioavailability **2021**,		1
170	Drug Absorption Parameters Obtained Using the Isolated Perfused Rat Lung Model Are Predictive of Rat In Vivo Lung Absorption. *AAPS Journal*, **2020**, 22, 71	3.7	8
169	Regional Intestinal Drug Permeability and Effects of Permeation Enhancers in Rat. *Pharmaceutics*, **2020**, 12,	6.4	9
168	Antibody-Drug Conjugates and Targeted Treatment Strategies for Hepatocellular Carcinoma: A Drug-Delivery Perspective. *Molecules*, **2020**, 25,	4.8	8
167	The In Vivo Effect of Transcellular Permeation Enhancers on the Intestinal Permeability of Two Peptide Drugs Enalaprilat and Hexarelin. *Pharmaceutics*, **2020**, 12,	6.4	10
166	Model-Informed Drug Discovery and Development Strategy for the Rapid Development of Anti-Tuberculosis Drug Combinations. *Applied Sciences (Switzerland)*, **2020**, 10, 2376	2.6	4
165	ICH M9 Guideline in Development on Biopharmaceutics Classification System-Based Biowaivers: An Industrial Perspective from the IQ Consortium. *Molecular Pharmaceutics*, **2020**, 17, 361-372	5.6	10
164	Prevention of Rat Intestinal Injury with a Drug Combination of Melatonin and Misoprostol. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	2
163	Pulmonary drug absorption and systemic exposure in human: Predictions using physiologically based biopharmaceutics modeling. *European Journal of Pharmaceutics and Biopharmaceutics*, **2020**, 156, 191-202	5.7	6
162	Effects of a novel combination of orlistat and acarbose on tolerability, appetite, and glucose metabolism in persons with obesity. *Obesity Science and Practice*, **2020**, 6, 313-323	2.6	12

161	The Critical Role of Passive Permeability in Designing Successful Drugs. *ChemMedChem*, **2020**, 15, 1862-1874	3.7	15
160	Intestinal Permeability and Drug Absorption: Predictive Experimental, Computational and In Vivo Approaches. *Pharmaceutics*, **2019**, 11,	6.4	66
159	Pulmonary Dissolution of Poorly Soluble Compounds Studied in an ex Vivo Rat Lung Model. *Molecular Pharmaceutics*, **2019**, 16, 3053-3064	5.6	16
158	Gastroparesis, metoclopramide, and tardive dyskinesia: Risk revisited. *Neurogastroenterology and Motility*, **2019**, 31, e13617	4	25
157	Lipiodol-based emulsions used for transarterial chemoembolization and drug delivery: Effects of composition on stability and product quality. *Journal of Drug Delivery Science and Technology*, **2019**, 53, 101143	4.5	5
156	Liver Cancer Cell Lines Treated with Doxorubicin under Normoxia and Hypoxia: Cell Viability and Oncologic Protein Profile. *Cancers*, **2019**, 11,	6.6	23
155	Physiologically Based Pharmacokinetic Model of Itraconazole and Two of Its Metabolites to Improve the Predictions and the Mechanistic Understanding of CYP3A4 Drug-Drug Interactions. *Drug Metabolism and Disposition*, **2018**, 46, 1420-1433	4	15
154	Pulmonary absorption - estimation of effective pulmonary permeability and tissue retention of ten drugs using an ex vivo rat model and computational analysis. *European Journal of Pharmaceutics and Biopharmaceutics*, **2018**, 124, 1-12	5.7	22
153	Reply to "Comment on "In Vivo Drug Delivery Performance of Lipiodol-Based Emulsion or Drug-Eluting Beads in Patients with Hepatocellular Carcinoma"". *Molecular Pharmaceutics*, **2018**, 15, 336-340	5.6	1
152	Porcine and Human In Vivo Simulations for Doxorubicin-Containing Formulations Used in Locoregional Hepatocellular Carcinoma Treatment. *AAPS Journal*, **2018**, 20, 96	3.7	3
151	Formulation predictive dissolution (fPD) testing to advance oral drug product development: An introduction to the US FDA funded "21st Century BA/BE" project. *International Journal of Pharmaceutics*, **2018**, 548, 120-127	6.5	27
150	A Model-Based Approach To Assessing the Importance of Intracellular Binding Sites in Doxorubicin Disposition. *Molecular Pharmaceutics*, **2017**, 14, 686-698	5.6	13
149	In Vivo Drug Delivery Performance of Lipiodol-Based Emulsion or Drug-Eluting Beads in Patients with Hepatocellular Carcinoma. *Molecular Pharmaceutics*, **2017**, 14, 448-458	5.6	20
148	Lipiodol does not affect the tissue distribution of intravenous doxorubicin infusion in pigs. *Journal of Pharmacy and Pharmacology*, **2017**, 69, 135-142	4.8	6
147	Regional Intestinal Permeability in Rats: A Comparison of Methods. *Molecular Pharmaceutics*, **2017**, 14, 4252-4261	5.6	30
146	Preclinical Effect of Absorption Modifying Excipients on Rat Intestinal Transport of Model Compounds and the Mucosal Barrier Marker Cr-EDTA. *Molecular Pharmaceutics*, **2017**, 14, 4243-4251	5.6	26
145	In Vivo Mechanisms of Intestinal Drug Absorption from Aprepitant Nanoformulations. *Molecular Pharmaceutics*, **2017**, 14, 4233-4242	5.6	36
144	An Intraprostatic Modified Release Formulation of Antiandrogen 2-Hydroxyflutamide for Localized Prostate Cancer. *Journal of Urology*, **2017**, 198, 1333-1339	2.5	6

143	Optimization of the Ussing chamber setup with excised rat intestinal segments for dissolution/permeation experiments of poorly soluble drugs. *Drug Development and Industrial Pharmacy*, **2017**, 43, 338-346	3.6	8
142	IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 2: An introduction to the simulation exercise and overview of results. *European Journal of Pharmaceutical Sciences*, **2017**, 96, 610-625	5.1	43
141	IMI - oral biopharmaceutics tools project - evaluation of bottom-up PBPK prediction success part 1: Characterisation of the OrBiTo database of compounds. *European Journal of Pharmaceutical Sciences*, **2017**, 96, 598-609	5.1	30
140	IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 3: Identifying gaps in system parameters by analysing In Silico performance across different compound classes. *European Journal of Pharmaceutical Sciences*, **2017**, 96, 626-642	5.1	34
139	In Vitro Release Mechanisms of Doxorubicin From a Clinical Bead Drug-Delivery System. *Journal of Pharmaceutical Sciences*, **2016**, 105, 3387-3398	3.9	30
138	Regional Intestinal Permeability of Three Model Drugs in Human. *Molecular Pharmaceutics*, **2016**, 13, 3013-21	5.6	45
137	Regional Intestinal Permeability in Dogs: Biopharmaceutical Aspects for Development of Oral Modified-Release Dosage Forms. *Molecular Pharmaceutics*, **2016**, 13, 3022-33	5.6	27
136	Human in vivo regional intestinal permeability: quantitation using site-specific drug absorption data. *Molecular Pharmaceutics*, **2015**, 12, 2026-39	5.6	46
135	Direct In Vivo Human Intestinal Permeability (Peff) Determined with Different Clinical Perfusion and Intubation Methods. *Journal of Pharmaceutical Sciences*, **2015**, 104, 2702-26	3.9	66
134	Translating Human Effective Jejunal Intestinal Permeability to Surface-Dependent Intrinsic Permeability: a Pragmatic Method for a More Mechanistic Prediction of Regional Oral Drug Absorption. *AAPS Journal*, **2015**, 17, 1177-92	3.7	14
133	Effect on the Gastrointestinal Absorption of Drugs from Different Classes in the Biopharmaceutics Classification System, When Treating with Liraglutide. *Molecular Pharmaceutics*, **2015**, 12, 4166-73	5.6	11
132	In vivo methods for drug absorption - comparative physiologies, model selection, correlations with in vitro methods (IVIVC), and applications for formulation/API/excipient characterization including food effects. *European Journal of Pharmaceutical Sciences*, **2014**, 57, 99-151	5.1	196
131	Evaluation of the use of Classical Nucleation Theory for predicting intestinal crystalline precipitation of two weakly basic BSC class II drugs. *European Journal of Pharmaceutical Sciences*, **2014**, 53, 17-27	5.1	16
130	The biopharmaceutics risk assessment roadmap for optimizing clinical drug product performance. *Journal of Pharmaceutical Sciences*, **2014**, 103, 3377-3397	3.9	45
129	The effects of lipiodol and cyclosporin A on the hepatobiliary disposition of doxorubicin in pigs. *Molecular Pharmaceutics*, **2014**, 11, 1301-13	5.6	9
128	Human in vivo regional intestinal permeability: importance for pharmaceutical drug development. *Molecular Pharmaceutics*, **2014**, 11, 12-23	5.6	60
127	Pharmacokinetics of an injectable modified-release 2-hydroxyflutamide formulation in the human prostate gland using a semiphysiologically based biopharmaceutical model. *Molecular Pharmaceutics*, **2014**, 11, 3097-111	5.6	15
126	Investigation of hepatobiliary disposition of doxorubicin following intrahepatic delivery of different dosage forms. *Molecular Pharmaceutics*, **2014**, 11, 131-44	5.6	20

125	Passive lipoidal diffusion and carrier-mediated cell uptake are both important mechanisms of membrane permeation in drug disposition. *Molecular Pharmaceutics*, **2014**, 11, 1727-38	5.6	87
124	Treatment of intermediate stage hepatocellular carcinoma: a review of intrahepatic doxorubicin drug-delivery systems. *Therapeutic Delivery*, **2014**, 5, 447-66	3.8	22
123	High-resolution mass spectrometric investigation of the phase I and II metabolites of finasteride in pig plasma, urine and bile. *Xenobiotica*, **2014**, 44, 498-510	2	2
122	Effects of verapamil on the pharmacokinetics and hepatobiliary disposition of fexofenadine in pigs. *European Journal of Pharmaceutical Sciences*, **2014**, 57, 214-23	5.1	4
121	Regional intestinal drug permeation: biopharmaceutics and drug development. *European Journal of Pharmaceutical Sciences*, **2014**, 57, 333-41	5.1	66
120	Combined in vitro-in vivo approach to assess the hepatobiliary disposition of a novel oral thrombin inhibitor. *Molecular Pharmaceutics*, **2013**, 10, 4252-62	5.6	13
119	In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim. *European Journal of Pharmaceutical Sciences*, **2013**, 49, 679-98	5.1	120
118	Binding processes determine the stereoselective intestinal and hepatic extraction of verapamil in vivo. *Molecular Pharmaceutics*, **2012**, 9, 3034-45	5.6	5
117	The fraction dose absorbed, in humans, and high jejunal human permeability relationship. *Molecular Pharmaceutics*, **2012**, 9, 1847-51	5.6	64
116	In vivo dog intestinal precipitation of mebendazole: a basic BCS class II drug. *Molecular Pharmaceutics*, **2012**, 9, 2903-11	5.6	36
115	The pharmacokinetics and hepatic disposition of repaglinide in pigs: mechanistic modeling of metabolism and transport. *Molecular Pharmaceutics*, **2012**, 9, 823-41	5.6	22
114	Extensive intestinal glucuronidation of raloxifene in vivo in pigs and impact for oral drug delivery. *Xenobiotica*, **2012**, 42, 917-28	2	11
113	Biliary excretion of ximelagatran and its metabolites and the influence of erythromycin following intraintestinal administration to healthy volunteers. *Journal of Clinical Pharmacology*, **2011**, 51, 770-83	2.9	3
112	Drug metabolism of CYP3A4, CYP2C9 and CYP2D6 substrates in pigs and humans. *European Journal of Pharmaceutical Sciences*, **2011**, 43, 89-98	5.1	44
111	The BCS, BDDCS, and regulatory guidances. *Pharmaceutical Research*, **2011**, 28, 1774-8	4.5	70
110	Effects of ketoconazole on the in vivo biotransformation and hepatobiliary transport of the thrombin inhibitor AZD0837 in pigs. *Drug Metabolism and Disposition*, **2011**, 39, 239-46	4	7
109	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole. *Drug Metabolism and Disposition*, **2011**, 39, 847-57	4	15
108	Gastrointestinal metabolism of a vegetable-oil emulsion in healthy subjects. *American Journal of Clinical Nutrition*, **2010**, 92, 515-24	7	25

107	Effect of a single gemfibrozil dose on the pharmacokinetics of rosuvastatin in bile and plasma in healthy volunteers. *Journal of Clinical Pharmacology*, **2010**, 50, 1039-49	2.9	15
106	High-permeability criterion for BCS classification: segmental/pH dependent permeability considerations. *Molecular Pharmaceutics*, **2010**, 7, 1827-34	5.6	84
105	Hepatic disposition of ximelagatran and its metabolites in pig; prediction of the impact of membrane transporters through a simple disposition model. *Pharmaceutical Research*, **2010**, 27, 597-607	4.5	3
104	The multiple depletion curves method provides accurate estimates of intrinsic clearance (CLint), maximum velocity of the metabolic reaction (Vmax), and Michaelis constant (Km): accuracy and robustness evaluated through experimental data and Monte Carlo simulations. *Drug Metabolism and Disposition*, **2009**, 37, 47-58	4	35
103	Different effects of ketoconazole on the stereoselective first-pass metabolism of R/S-verapamil in the intestine and the liver: important for the mechanistic understanding of first-pass drug-drug interactions. *Drug Metabolism and Disposition*, **2009**, 37, 2186-96	4	16
102	Identification of finasteride metabolites in human bile and urine by high-performance liquid chromatography/tandem mass spectrometry. *Drug Metabolism and Disposition*, **2009**, 37, 2008-17	4	16
101	Improving glucocorticoid replacement therapy using a novel modified-release hydrocortisone tablet: a pharmacokinetic study. *European Journal of Endocrinology*, **2009**, 161, 119-30	6.5	129
100	The effect of St. John's wort on the pharmacokinetics, metabolism and biliary excretion of finasteride and its metabolites in healthy men. *European Journal of Pharmaceutical Sciences*, **2009**, 36, 433-43	5.1	29
99	Online capillary solid phase extraction and liquid chromatographic separation with quantitative tandem mass spectrometric detection (SPE-LC-MS/MS) of ximelagatran and its metabolites in a complex matrix. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2009**, 877, 291-7	3.2	5
98	Toward an increased understanding of the barriers to colonic drug absorption in humans: implications for early controlled release candidate assessment. *Molecular Pharmaceutics*, **2009**, 6, 60-73	5.6	97
97	Ethanol-drug absorption interaction: potential for a significant effect on the plasma pharmacokinetics of ethanol vulnerable formulations. *Molecular Pharmaceutics*, **2009**, 6, 1429-40	5.6	36
96	Enterohepatic disposition of rosuvastatin in pigs and the impact of concomitant dosing with cyclosporine and gemfibrozil. *Drug Metabolism and Disposition*, **2009**, 37, 2349-58	4	27
95	Replacement therapy of oral hydrocortisone in adrenal insufficiency: the influence of gastrointestinal factors. *Expert Opinion on Drug Metabolism and Toxicology*, **2008**, 4, 749-58	5.5	15
94	In Vivo Permeability Studies in the Gastrointestinal Tract of Humans. *Methods and Principles in Medicinal Chemistry*, **2008**, 185-219	0.4	1
93	Intestinal and hepatobiliary transport of ximelagatran and its metabolites in pigs. *Drug Metabolism and Disposition*, **2008**, 36, 1519-28	4	19
92	Application of the Biopharmaceutics Classification System Now and in the Future. *Methods and Principles in Medicinal Chemistry*, **2008**, 521-558	0.4	1
91	The use of BDDCS in classifying the permeability of marketed drugs. *Pharmaceutical Research*, **2008**, 25, 483-8	4.5	111
90	Pharmacokinetics of gefitinib in humans: the influence of gastrointestinal factors. *International Journal of Pharmaceutics*, **2007**, 341, 134-42	6.5	50

89	Animal data: the contributions of the Ussing Chamber and perfusion systems to predicting human oral drug delivery in vivo. *Advanced Drug Delivery Reviews*, **2007**, 59, 1103-20	18.5	117
88	Modeling gastrointestinal drug absorption requires more in vivo biopharmaceutical data: experience from in vivo dissolution and permeability studies in humans. *Current Drug Metabolism*, **2007**, 8, 645-57	3.5	75
87	Simultaneous assessment of lipid classes and bile acids in human intestinal fluid by solid-phase extraction and HPLC methods. *Journal of Lipid Research*, **2007**, 48, 242-51	6.3	43
86	Biliary secretion of rosuvastatin and bile acids in humans during the absorption phase. *European Journal of Pharmaceutical Sciences*, **2006**, 29, 205-14	5.1	50
85	First-pass effects of verapamil on the intestinal absorption and liver disposition of fexofenadine in the porcine model. *Drug Metabolism and Disposition*, **2006**, 34, 1182-9	4	34
84	Presentation of a structurally diverse and commercially available drug data set for correlation and benchmarking studies. *Journal of Medicinal Chemistry*, **2006**, 49, 6660-71	8.3	40
83	Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. *Pharmaceutical Research*, **2006**, 23, 1675-86	4.5	293
82	A clinical single-pass perfusion investigation of the dynamic in vivo secretory response to a dietary meal in human proximal small intestine. *Pharmaceutical Research*, **2006**, 23, 742-51	4.5	66
81	The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension. *Journal of Pharmacy and Pharmacology*, **2005**, 57, 273-85	4.8	134
80	The effects of food on the dissolution of poorly soluble drugs in human and in model small intestinal fluids. *Pharmaceutical Research*, **2005**, 22, 2141-51	4.5	226
79	Transport characteristics of fexofenadine in the Caco-2 cell model. *Pharmaceutical Research*, **2004**, 21, 1398-404	4.5	105
78	Simultaneous quantification of the enantiomers of verapamil and its N-demethylated metabolite in human plasma using liquid chromatography-tandem mass spectrometry. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2004**, 804, 303-11	3.2	17
77	St John's wort decreases the bioavailability of R- and S-verapamil through induction of the first-pass metabolism. *Clinical Pharmacology and Therapeutics*, **2004**, 75, 298-309	6.1	96
76	Intestinal and blood-brain drug transport: beyond involvement of a single transport function. *Drug Discovery Today: Technologies*, **2004**, 1, 417-22	7.1	11
75	Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. *Molecular Pharmaceutics*, **2004**, 1, 85-96	5.6	597
74	Characterization of jejunal absorption and apical efflux of ropivacaine, lidocaine and bupivacaine in the rat using in situ and in vitro absorption models. *European Journal of Pharmaceutical Sciences*, **2004**, 21, 553-60	5.1	62
73	St John's Wort Decreases the Bioavailability of R- and S-verapamil Through Induction of the First-pass Metabolism **2004**, 75, 298		2
72	Regional transport and metabolism of ropivacaine and its CYP3A4 metabolite PPX in human intestine. *Journal of Pharmacy and Pharmacology*, **2003**, 55, 963-72	4.8	24

71	Intestinal drug absorption and bioavailability: beyond involvement of single transport function. *Journal of Pharmacy and Pharmacology*, **2003**, 55, 429-33	4.8	21
70	Chemotherapy and antiangiogenesis--drug-specific, dose-related effects. *Acta Oncologica*, **2003**, 42, 294-303	3.3	54
69	VOLSURF: A Tool for Drug ADME-Properties Prediction. *Methods and Principles in Medicinal Chemistry*, **2003**, 406-419	0.4	15
68	Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets. *Clinical Neuropharmacology*, **2003**, 26, 156-63	1.4	172
67	The Importance of Gut Wall Metabolism in Determining Drug Bioavailability. *Methods and Principles in Medicinal Chemistry*, **2003**, 311-328	0.4	6
66	Calculated Molecular Properties and Multivariate Statistical Analysis in Absorption Prediction. *Methods and Principles in Medicinal Chemistry*, **2003**, 358-405	0.4	8
65	Gastrointestinal Dissolution and Absorption of Drugs. *Methods and Principles in Medicinal Chemistry*, **2003**, 189-214	0.4	3
64	Factors Influencing the Water Solubilities of Crystalline Drugs. *Methods and Principles in Medicinal Chemistry*, **2003**, 232-242	0.4	1
63	Hepatic Transport. *Methods and Principles in Medicinal Chemistry*, **2003**, 288-310	0.4	0
62	Modified Cell Lines. *Methods and Principles in Medicinal Chemistry*, **2003**, 329-338	0.4	
61	Intestinal Absorption: The Role of Polar Surface Area. *Methods and Principles in Medicinal Chemistry*, **2003**, 339-357	0.4	6
60	Simulation of Absorption, Metabolism, and Bioavailability. *Methods and Principles in Medicinal Chemistry*, **2003**, 420-443	0.4	5
59	Prediction of Bioavailability. *Methods and Principles in Medicinal Chemistry*, **2003**, 444-460	0.4	1
58	Application of the Biopharmaceutic Classification System Now and in the Future. *Methods and Principles in Medicinal Chemistry*, **2003**, 493-531	0.4	1
57	Prodrugs. *Methods and Principles in Medicinal Chemistry*, **2003**, 532-546	0.4	3
56	Modern Delivery Strategies: Physiological Considerations for Orally Administered Medications. *Methods and Principles in Medicinal Chemistry*, **2003**, 547-568	0.4	
55	Caco-2 and Emerging Alternatives for Prediction of Intestinal Drug Transport: A General Overview. *Methods and Principles in Medicinal Chemistry*, **2003**, 72-89	0.4	10
54	Use of Animals for the Determination of Absorption and Bioavailability. *Methods and Principles in Medicinal Chemistry*, **2003**, 132-154	0.4	3

53	In Vivo Permeability Studies in the Gastrointestinal Tract of Humans. *Methods and Principles in Medicinal Chemistry*, **2003**, 155-188	0.4	5
52	Aqueous Solubility in Discovery, Chemistry, and Assay Changes. *Methods and Principles in Medicinal Chemistry*, **2003**, 215-231	0.4	13
51	Towards P-Glycoprotein Structure-Activity Relationships. *Methods and Principles in Medicinal Chemistry*, **2003**, 461-492	0.4	3
50	Transporters in the GI Tract. *Methods and Principles in Medicinal Chemistry*, **2003**, 243-287	0.4	3
49	High-Throughput Measurement of log D and pKa. *Methods and Principles in Medicinal Chemistry*, **2003**, 21-45	0.4	13
48	High-throughput Measurement of Permeability Profiles. *Methods and Principles in Medicinal Chemistry*, **2003**, 46-71	0.4	10
47	Enantioselective transport and CYP3A4-mediated metabolism of R/S-verapamil in Caco-2 cell monolayers. *European Journal of Pharmaceutical Sciences*, **2003**, 19, 57-65	5.1	19
46	Pulmonary absorption rate and bioavailability of drugs in vivo in rats: structure-absorption relationships and physicochemical profiling of inhaled drugs. *Journal of Pharmaceutical Sciences*, **2003**, 92, 1216-33	3.9	106
45	Multiple transport mechanisms involved in the intestinal absorption and first-pass extraction of fexofenadine. *Clinical Pharmacology and Therapeutics*, **2003**, 74, 423-36	6.1	71
44	The effect of ketoconazole on the in vivo intestinal permeability of fexofenadine using a regional perfusion technique. *British Journal of Clinical Pharmacology*, **2003**, 55, 182-90	3.8	60
43	Clinical pharmacokinetics of atorvastatin. *Clinical Pharmacokinetics*, **2003**, 42, 1141-60	6.2	391
42	Absorption/metabolism of sulforaphane and quercetin, and regulation of phase II enzymes, in human jejunum in vivo. *Drug Metabolism and Disposition*, **2003**, 31, 805-13	4	183
41	Cell Cultures in Drug Discovery: An Industrial Perspective. *Methods and Principles in Medicinal Chemistry*, **2003**, 90-131	0.4	13
40	Physico-Chemical Approaches to Drug Absorption. *Methods and Principles in Medicinal Chemistry*, **2003**, 1-20	0.4	2
39	Drug absorption from the isolated perfused rat lung--correlations with drug physicochemical properties and epithelial permeability. *Journal of Drug Targeting*, **2003**, 11, 61-74	5.4	77
38	Comparison of human duodenum and Caco-2 gene expression profiles for 12,000 gene sequences tags and correlation with permeability of 26 drugs. *Pharmaceutical Research*, **2002**, 19, 1400-16	4.5	305
37	Miniaturized nebulization catheters: a new approach for delivery of defined aerosol doses to the rat lung. *Journal of Aerosol Medicine and Pulmonary Drug Delivery*, **2002**, 15, 283-96		32
36	High airway-to-blood transport of an opioid tetrapeptide in the isolated rat lung after aerosol delivery. *Peptides*, **2002**, 23, 469-78	3.8	18

35	Regional differences in bioavailability of an opioid tetrapeptide in vivo in rats after administration to the respiratory tract. *Peptides*, **2002**, 23, 479-88	3.8	15
34	Effects of cholesterol and model transmembrane proteins on drug partitioning into lipid bilayers as analysed by immobilized-liposome chromatography. *Journal of Pharmacy and Pharmacology*, **2001**, 53, 1477-87	4.8	21
33	Human jejunal permeability of two polar drugs: cimetidine and ranitidine. *Pharmaceutical Research*, **2001**, 18, 742-4	4.5	47
32	Direct estimation of the in vivo dissolution of spironolactone, in two particle size ranges, using the single-pass perfusion technique (Loc-I-Gut) in humans. *European Journal of Pharmaceutical Sciences*, **2001**, 12, 239-50	5.1	33
31	Dissolution of hydrocortisone in human and simulated intestinal fluids. *Pharmaceutical Research*, **2000**, 17, 183-9	4.5	66
30	No evidence for the involvement of the multidrug resistance-associated protein and/or the monocarboxylic acid transporter in the intestinal transport of fluvastatin in the rat. *AAPS PharmSci*, **2000**, 2, E26		11
29	SPR biosensor studies of the direct interaction between 27 drugs and a liposome surface: correlation with fraction absorbed in humans. *Journal of Medicinal Chemistry*, **2000**, 43, 2083-6	8.3	118
28	The effect of ketoconazole on the jejunal permeability and CYP3A metabolism of (R/S)-verapamil in humans. *British Journal of Clinical Pharmacology*, **1999**, 48, 180-9	3.8	59
27	Surface activity and concentration dependent intestinal permeability in the rat. *Pharmaceutical Research*, **1999**, 16, 97-102	4.5	10
26	A comparison between direct determination of in vivo dissolution and the deconvolution technique in humans. *European Journal of Pharmaceutical Sciences*, **1999**, 8, 19-27	5.1	30
25	Water-soluble beta-cyclodextrins in paediatric oral solutions of spironolactone: preclinical evaluation of spironolactone bioavailability from solutions of beta-cyclodextrin derivatives in rats. *Journal of Pharmacy and Pharmacology*, **1998**, 50, 611-9	4.8	28
24	Concentration- and region-dependent intestinal permeability of fluvastatin in the rat. *Journal of Pharmacy and Pharmacology*, **1998**, 50, 737-44	4.8	21
23	Jejunal absorption and metabolism of R/S-verapamil in humans. *Pharmaceutical Research*, **1998**, 15, 856-62	4.5	81
22	Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach. *Journal of Medicinal Chemistry*, **1998**, 41, 4939-49	8.3	380
21	Human jejunal effective permeability and its correlation with preclinical drug absorption models. *Journal of Pharmacy and Pharmacology*, **1997**, 49, 627-38	4.8	143
20	A residence-time distribution analysis of the hydrodynamics within the intestine in man during a regional single-pass perfusion with Loc-I-Gut: in-vivo permeability estimation. *Journal of Pharmacy and Pharmacology*, **1997**, 49, 682-6	4.8	34
19	Regional intestinal permeability in rats of compounds with different physicochemical properties and transport mechanisms. *Journal of Pharmacy and Pharmacology*, **1997**, 49, 687-90	4.8	75
18	Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. *Clinical Pharmacokinetics*, **1997**, 32, 403-25	6.2	379

17	Characterization of fluids from the stomach and proximal jejunum in men and women. *Pharmaceutical Research*, **1997**, 14, 497-502	4.5	308
16	Human intestinal permeability of piroxicam, propranolol, phenylalanine, and PEG 400 determined by jejunal perfusion. *Pharmaceutical Research*, **1997**, 14, 1127-32	4.5	45
15	Rat jejunal permeability and metabolism of mu-selective tetrapeptides in gastrointestinal fluids from humans and rats. *Pharmaceutical Research*, **1997**, 14, 1780-5	4.5	25
14	A new approach for direct in vivo dissolution studies of poorly soluble drugs. *Pharmaceutical Research*, **1997**, 14, 1490-2	4.5	23
13	Is the jejunal permeability in rats age-dependent?. *Pharmaceutical Research*, **1997**, 14, 1278-81	4.5	11
12	Comparison between permeability coefficients in rat and human jejunum. *Pharmaceutical Research*, **1996**, 13, 1336-42	4.5	338
11	Jejunal permeability and hepatic extraction of fluvastatin in humans. *Clinical Pharmacology and Therapeutics*, **1996**, 60, 493-503	6.1	75
10	Permeability and clearance views of drug absorption: a commentary. *Journal of Pharmacokinetics and Pharmacodynamics*, **1995**, 23, 333-43		19
9	A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. *Pharmaceutical Research*, **1995**, 12, 413-20	4.5	3518
8	Regional rectal perfusion: a new in vivo approach to study rectal drug absorption in man. *Pharmaceutical Research*, **1995**, 12, 426-32	4.5	35
7	Does fluid flow across the intestinal mucosa affect quantitative oral drug absorption? Is it time for a reevaluation?. *Pharmaceutical Research*, **1995**, 12, 1573-82	4.5	80
6	The lack of effect of induced net fluid absorption on the in vivo permeability of terbutaline in the human jejunum. *Journal of Drug Targeting*, **1995**, 3, 191-200	5.4	43
5	Experimental estimation of the effective unstirred water layer thickness in the human jejunum, and its importance in oral drug absorption. *European Journal of Pharmaceutical Sciences*, **1995**, 3, 247-253	5.1	79
4	The influence of net water absorption on the permeability of antipyrine and levodopa in the human jejunum. *Pharmaceutical Research*, **1994**, 11, 1540-7	4.5	40
3	Dose-dependent intestinal absorption and significant intestinal excretion (exsorption) of the beta-blocker pafenolol in the rat. *Pharmaceutical Research*, **1993**, 10, 727-31	4.5	34
2	Regional gastrointestinal absorption of the beta-blocker pafenolol in the rat and intestinal transit rate determined by movement of 14C-polyethylene glycol (PEG) 4000. *Pharmaceutical Research*, **1993**, 10, 130-5	4.5	33
1	Regional jejunal perfusion, a new in vivo approach to study oral drug absorption in man. *Pharmaceutical Research*, **1992**, 9, 1243-51	4.5	178